Home > News > Social and Economic Benefits of Early Optimised Treatment for Parkinson’s Disease Patients – Improved Quality of Life and Greater Productivity
Movement Disorders, Parkinson's Disease
Read Time: 2 mins

Social and Economic Benefits of Early Optimised Treatment for Parkinson’s Disease Patients – Improved Quality of Life and Greater Productivity

Published Online: May 15th 2012 European Neurological Review, 2012;7(2):113–7 DOI: http://doi.org/10.17925/ENR.2012.07.02.113
Authors: Johan Lökk, Ulf Persson, Michael Wainwright
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

From a broad societal perspective, the economic burden of Parkinson’s disease ranges from direct medication expenses to costs associated with home help and lost production. The last two generally arise in the more advanced stages of the disease. Savings are nevertheless possible and the two main ways of attaining this are by slowing down disease progression and reducing the time patients spend in off-periods. Earlier onset of optimised treatment, both in the initial and later disease stages, has the potential to achieve both. We highlight examples of advanced therapies that alleviate severe motor symptoms and thereby prolong the time patients can remain in their own homes and at their places of work. Health economic calculations for two forms of advanced therapy, continuous dopaminergic stimulation via pumps and deep brain stimulation, are also shown.

Keywords

Parkinson’s disease, quality of life, advanced therapies, onset of treatment, socioeconomic burden, cost-utility

Article:

Like other chronic neurodegenerative diseases, Parkinson’s disease (PD) is associated with an impaired quality of life (QoL) for patients and costs to society. In Sweden at 2011 prices, the overall average cost per patient and year has been estimated at SEK (Swedish crowns) 148,000 or €16,500.1 In 2005 in Europe, the direct cost was estimated as €10.7 billion per year, but it was considered that the total costs may be around 40 % more.2 Significantly, future costs in developed countries were predicted to double by 2030.

Most of the costs associated with PD fall outside of the healthcare system, e.g. they are due to home care or lost productivity. A growing body of expertise believes that allocating more resources to early, optimised therapy can offset direct medication costs by raising patient QoL. This should reduce their need for home care and prolong the time they spend at work. We provide support for this view and show how economic simulation modelling can help generate meaningful cost-utility data.

Socioeconomic Experiences of Focused Treatment in Haemophilia
In developing countries with a per capita gross national product (GNP) of less than US$2,000, few citizens with haemophilia live beyond the age of nineteen. Many do not survive childhood. However, survival to adulthood and beyond increases approximately fivefold if these people have access to a specific haemophilia treatment centre (HTC).

Data collected by the World Federation of Haemophilia (WFH)3 clearly show that even minimal level treatment at a HTC boosted recovery from bleeding episodes and increased survival to adulthood. This resulted in a quicker return to school or work, as well as preserved functional independence. Absenteeism decreased, productivity improved and the burden on caregivers was reduced.

A relatively modest investment in the health of haemophilia sufferers thus benefits both government and society since as adults they are able to work and contribute to the community. The long-term financial consequences of higher morbidity are avoided.

This simple yet dramatic example has parallels with the treatment of PD in western countries. Although the costs of treating PD may be higher than the expenses of running a basic HTC, the economic resources of industrialised nations are correspondingly greater. So just as it makes economic sense for countries with even limited resources to provide organised haemophilia care, developed countries should evaluate the cost benefits of the therapeutic options available forPD. Expenses associated with providing optimised treatment as early as possible could be more than offset by improved outcome.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

Johan Lökk has received honoraria from Boehringer Ingelheim for lectures and has participated in clinical trials for Boehringer Ingelheim. Ulf Persson and Michael Wainwright have no conflicts of interest to declare.

Correspondence

Johan Lökk, Professor and Head Physician, Geriatric Department, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. E: johan.lokk@karolinska.se

Support

The authors thank Susanna Lindvall for her valuable advice and encouragement.

Received

2012-02-17T00:00:00

References

  1. Lökk J, Borg S, Svensson J, et al., Drug and treatment costs in Parkinson’s disease patients in Sweden, Acta Neurol Scand, 2012;125(2):142–7.
  2. Dodel R, Interpreting health economics data in Parkinson’s disease, Eur Neurol Rev, 2011;6(Suppl. 1):13–6.
  3. Brooker M, The World Federation of Hemophilia’s third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary, Haemophilia, 2004;10(3):290–4.
  4. Lotharius J, Brundin P, Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson’s disease, Hum Mol Genet, 2002;11:2395–407.
  5. Tolosa E, Gaig C, Santamaría J, Compta Y, Diagnosis and the premotor phase of Parkinson disease, Neurology, 2009;72(7 Suppl.):S12–20.
  6. Rio LM, Lindvall S, Lökk J, Wainwright M, Redressing the balance in Parkinson’s disease management with a greater focus on non-motor symptoms and care-giver health, Eur Neurol Rev, 2009;4(1):31-34.
  7. Jankovic J, Aguilar LG, Current approaches to the treatment of Parkinson’s disease, Neuropsych Dis Treat, 2008;4(4):743–57.
  8. Rascol O, Fitzer-Attas CJ, Hauser R, et al., A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes, Lancet Neurol, 2011;10(5):415–23.
  9. Lökk J, Reduced life-space of non-professional caregivers to Parkinson's disease patients with increased disease duration, Clin Neurol Neurosurgery, 2009;111:583–7.
  10. Sanford M, Scott LJ, Rotigotine transdermal patch: a review of its use in the treatment of Parkinson’s disease, CNS Drugs, 2011;25(8):699–719.
  11. Antonini A, Continuous dopaminergic stimulation from theory to clinical practice, Parkinsonism Relat Disord, 2007;13 Suppl.:S24–8.
  12. Storch A, Treating patients with deep brain stimulation or Duodopa – pros and cons, Eur Neurol Dis, 2007;2:14–7.
  13. Chaudhuri KR, Odin P, Antonini A, et al., Parkinson’s disease: the non-motor issues, Parkinsonism Relat Disord, 2011;17(10):717–23.
  14. Lökk J, Lack of information and access to advanced treatment for Parkinson's disease patients, J Multidiscip Healthc, 2011;4:433–9.
  15. Hagell P, Nordling S, Reimer J, et al., Resource use and costs in a Swedish cohort of patients with Parkinson’s disease, Mov Disord, 2002;17(6)1213–20.
  16. Keränen T, Kaakkola S, Sotaniemi K, Economic burden and quality of life impairment increase with severity of PD, Parkinsonism Relat Disord, 2003;9:163–8.
  17. Dodel R, The economic burden of Parkinson’s disease, Eur Neurol Rev, 2008;3(2):11–4.
  18. Schrag A, Banks P, Time of loss of employment in Parkinson’s disease, Mov Disord, 2006;21(11):1839–43.
  19. Willis M, Gradl B, Cost-utility-analysis of orphan drugs: case study of duodenal levodopa infusion versus standard treatment in patients with advanced Parkinson’s disease in Sweden, Presented at: ISPOR 13th Annual European Congress, Prague, Czech Republic, 6–9 November 2010.
  20. Persson U, Hjelmgren J, Hälso-och sjukvården behöver kunskap om hur befolkningen värderar hälsan (The healthcare organization needs knowledge of how the population values health, J Swed Med Ass, 2003; 100(43):3436–7.
  21. Puig-Junoy J, Puig Peiro R, Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson’s disease, Neurologia, 2009;24(4):220–9.
  22. Dams J, Bornschein B, Siebert U, et al., The costeffectiveness of deep brain stimulation for Parkinson’s disease, Presented at: the German Parkinson Congress, Kiel, Germany, 10–12 March 2011.

Further Resources

Share this Article
Related Content In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72